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Objective To assess the cost-effectiveness of the use of
cardiotocography (CTG) complemented with fetal
electrocardiography and ST analysis compared with the use of
CTG alone in term deliveries when a decision has been made to
use fetal monitoring with a scalp electrode.
Design A cost-effectiveness analysis based on a probabilistic
decision model incorporating relevant strategies and lifelong
outcomes.
Setting Maternity wards in Sweden.
Population Women with term fetuses after a clinical decision had
been made to apply a fetal scalp electrode for internal CTG.
Methods A decision model was used to compare the costs and
effects of two different treatment strategies. Baseline estimates were
derived from the literature. Discounted costs and quality-adjusted
life years (QALYs) were simulated over a lifetime horizon using
a probabilistic model.
Main outcome measures QALYs, incremental costs, and cost per
QALY gained expressed as incremental cost-effectiveness ratio
(ICER).
Results The analysis found an incremental effect of 0.005 QALYs
for ST analysis compared with CTG; the ST analysis strategy was
also moreover associated with a e56 decrease in costs, thus
dominating the CTG strategy. The probability that ST analysis is
cost-effective in comparison with CTG is high, irrespective of the
willingness-to-pay value for a QALY.
Conclusions Compared with CTG alone, ST analysis is cost-
effective when used in term high-risk deliveries in which there is
a need for internal fetal monitoring.
Keywords Cardiotocography, cerebral palsy, cost-effectiveness,
fetal monitoring, ST analysis.
Please cite this paper as: Heintz E, Brodtkorb T, Nelson N, Levin L. The long-term cost-effectiveness of fetal monitoring during labour: a comparison of
cardiotocography complemented with ST analysis versus cardiotocography alone. BJOG 2008;115:1676–1687.
Introduction
Fetal oxygen deﬁciency during birth can cause neurological
damage, and in 0.06%1 of all births in Sweden, the deﬁciency
is so severe that it leads to cerebral palsy or death. To take
appropriate actions to prevent hypoxia, fetal surveillance with
a scalp electrode is used in complicated deliveries. Currently,
the most common method of fetal surveillance with a scalp
electrode is internal cardiotocography (CTG). This method of
surveillance, however, has been demonstrated to have several
weaknesses and is therefore coupled with blood sampling to
achieve sufﬁcient speciﬁcity.1 To overcome some of these
weaknesses and enhance the detection of fetuses at risk of
hypoxia, a new method of combining CTG with ST analysis
has been developed. This method provides an automatic anal-
ysis of the ST interval in the electrocardiogram complex of the
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www.blackwellpublishing.com/bjog Fetal medicinefetus and, compared with CTG alone, is thought to rely less
on subjective interpretation. Several studies comparing CTG
with ST analysis have been published,2–4 and a Cochrane
review5 concluded that use of ST analysis, compared with
use of CTG alone, is associated with a reduction in cases of
metabolic acidosis and operative deliveries. However,
although the results of the Cochrane review indicate a positive
health effect of using ST analysis, these results are limited to
the intermediate outcome, namely metabolic acidosis. Hence,
whether using ST analysis actually improves the long-term
health outcome of the fetus has not been investigated.
As cost-effectiveness is a key criterion for decision makers
when deciding what healthcare interventions should be made
available in collectively funded healthcare systems,6 it is
important to compare the estimated lifelong effects with the
additional costs of adding ST analysis to the labour monitor-
ing regime. A short-term cost-analysis7 by the National Insti-
tute for Clinical Excellence (NICE), not taking the potential
effects on metabolic acidosis into account, compared the
higher equipment costs associated with ST analysis to the
costs-savings due to the lower risk of operative deliveries.
They reached the conclusion that the annual net cost of using
ST analysis in England would be £3.4 million but also stated
that a full economic analysis is required to assess the cost-
effectiveness of ST analysis.
When performing a cost-effectiveness analysis, the incre-
mental cost between two or more treatments is divided with
the incremental effect to form the incremental cost-effective-
ness ratio (ICER), which represents the additional cost one
has to pay to gain the effect unit of choice. When investigating
the cost-effectiveness, one should capture all relevant costs
and effects related to treatment choice.8 As the consequences
of metabolic acidosis when leading to cerebral palsy are life-
long and often severe, we would argue thata cost-effectiveness
analysis that only takes into account the intermediate out-
come, namely metabolic acidosis, is insufﬁcient. Rather, to
capture a broader understanding of health and wellbeing,
quality-adjusted life years (QALYs) is the recommended
outcome to be used in economic evaluations of healthcare
interventions.8 When calculating QALYs, the time spent in
a particular health state is weighted by a quality-adjustment
weight or utility, ranging between 0 (dead) and 1 (full health),
representing the quality of life associated with the health
state.8 Being a generic effect measure, the use of QALYs also
enables comparisons with other treatment areas.
As no study so far has investigated the long-term effects of
using ST analysis, data from different sources have to be syn-
thesisedandextrapolatedtoinvestigatethelong-termoutcome.
Decision-analytical models offer the possibility to synthesise
evidence from various sources and to extrapolate costs and
effects to a relevant setting and time intervals.9 The purpose
of our study was to, by employing a decision-analytic model,
undertake a cost-effectiveness analysis comparing the long-
term costs and effects (in terms of QALYs) of fetal monitoring
with ST analysis in comparison with those of using CTG alone.
Methods
To estimate the costs and effects of CTG complemented with
electrocardiography (ECG) and ST analysis, a decision tree
was used. By structuring the decision tree based on the results
of previously reported trials, we extrapolated the costs and
effects over a lifetime horizon, taking into account the prob-
ability of developing cerebral palsy and its effect on QALYs.
The analysis was performed from a Swedish societal perspec-
tive, including costs related to productivity losses due to mor-
bidity but excluding productivity losses due to mortality.
Costs are expressed in Euros (e) at the 2006 price level and
have been adjusted according to the Swedish Consumer Price
Index.10 The exchange rate used in the translation of costs was
9.4 Swedish Kronor per Euro.
Treatment strategies
The two treatment strategies analysed entailed delivering
a child with the support of either CTG alone or CTG com-
plemented with ECG and ST analysis (hereafter referred to as
‘ST analysis’). Internal CTG alone and ST analysis are used in
complicated term deliveries when a decision has been made to
attach a scalp electrode to the fetal head. The ST analysis
strategy uses the same technology as that of CTG but is com-
plemented with ECG and analysis of the ST waveform to rate
the signiﬁcance of abnormalities revealed by CTG. The fetal
ECG is automatically recorded, processed, and analysed by
the ST analysis monitor. When the CTG results are normal,
no attention is paid to abnormalities in the ST analysis. If
CTG results are abnormal or pathological, the severity of
the ST event determines what intervention is the most appro-
priate. For a preterminal CTG result, immediate delivery is
recommended.1 Fetal scalp blood sampling is optional for
both intervention strategies.5
Model structure
The simpliﬁed model structure is shown in Figure 1. The
structure of the decision tree is identical for both treatment
strategies, with only the probabilities of operative deliveries
and metabolic acidosis differing between the two. The long-
term extrapolation of the treatment effect is equal with regard
to the structure and probability of both alternatives.
In the model, a fetus being delivered faces a treatment-
speciﬁc probability of being born through spontaneous vag-
inal, instrumental vaginal, or caesarean delivery. This results
in different degrees of complications for both the fetus and
the mother in the two strategies. An assumption was made
that every delivery only results in the birth of one child. After
birth, the child may or may not display signs of metabolic
acidosis at a rate dependent on the treatment strategy. To the
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a direct correlation between incidence metabolic acidosis
and cerebral palsy. However, we do know that on its way from
an intrapartum hypoxic–ischaemic injury causing cerebral
palsy, the child progresses through newborn encephalopa-
thy.11 To take account of this connection, the transition from
signs of metabolic acidosis to cerebral palsy was therefore
modelled using levels of encephalopathy, through the child’s
level of base deﬁcit. Children were classiﬁed as having no,
minor, moderate, or severe encephalopathy.12 Children with
moderate or severe encephalopathy face an elevated risk of
dying or developing cerebral palsy, although they may also
develop without complications. Those classiﬁed as having no
or minor encephalopathy were assumed to develop without
any complications due to oxygen deﬁciency but may still face
a risk of developing cerebral palsy due to other causes. The
risk of cerebral palsy increases with the presence and severity
of encephalopathy.13 When deﬁning the different grades of
cerebral palsy, the following classiﬁcation was used: minimal
cerebral palsy is deﬁned as motor signs present but no func-
tional impairment, mild cerebral palsy as symptoms resulting
in some functional impairment, moderate cerebral palsy as
between mild and severe (e.g. ambulant with walking frame),
and severe cerebral palsy as ‘little purposeful voluntary action,
although function may be acquired, IQ permitting’.14
Probabilities
The probabilities used in the model are shown in Table 1.
Three randomised controlled trials (RCTs) investigated the
use of ST analysis compared with CTG2–4 alone with respect
to metabolic acidosis. Analysed in a meta-analysis, ST analysis
was demonstrated to have a relative risk of metabolic acidosis
of 0.64 (95% CI 0.41–1.00) compared with CTG,5 which is
used in our base-case analysis. One of the included trials, the
trial by Ojala et al.,4 has been criticised for using an inappro-
priate method of measuring metabolic acidosis, leading to
a misleading increase in the frequency of metabolic acidosis.21
We have therefore chosen to perform a sensitivity analysis
using a meta-analysis5 excluding this trial. However, the
RCT by Amer-Wa ˚hlin et al.2 has been criticised for not
including all observed cases of metabolic acidosis in the ST
analysis arm.22 This criticism was answered by the research
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Figure 1. The decision-analytic model. Different modes of delivery are
modelled as consequences of CTG and STAN. Regardless of the method of
delivery, there is a probability that the child may manifest metabolic
acidosis after birth. This probability differs between the two intervention
strategies. The probability that the child develops different grades of
newborn encephalopathy depends on the level of base deﬁcit. Moderate
or severe encephalopathy could lead to cerebral palsy of the different
degrees of severity, but could also lead to death or development without
complications. Children with no or mild encephalopathy face a risk of
developing cerebral palsy due to other causes than oxygen deﬁciency.
BD, base deﬁcit.
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Probabilities Mean value Distribution References
Maternal mortality after caesarean section 0.18 3 1023 Beta (36, 197 745) Hall and Bewley15
Maternal mortality after spontaneous and
instrumental vaginal delivery
0.21 3 1024 Beta (38, 1 845 919) Hall and Bewley15
Pulmonary embolism after caesarean section 0.51 3 1023 Beta (67, 132 342) The National Board of
Health and Welfare17
Deep vein thrombosis after caesarean section 0.11 3 1022 Beta (141, 132 268) The National Board of
Health and Welfare17
Cerebral thrombosis after caesarean section 0.24 3 1023 Beta (32, 132 377) The National Board of
Health and Welfare17
Pulmonary embolism after spontaneous and
instrumental vaginal delivery
0.11 3 1023 Beta (131, 1 148 627) The National Board of
Health and Welfare17
Deep vein thrombosis after spontaneous and
instrumental vaginal delivery
0.28 3 1023 Beta (326, 1 148 432) The National Board of
Health and Welfare17
Cerebral thrombosis after spontaneous and
instrumental vaginal delivery
0.91 3 1024 Beta (104, 1 148 654) The National Board of
Health and Welfare17
Blood transfusions after caesarean section 0.46 3 1022 Beta (687, 149 621) The National Board of
Health and Welfare17
Blood transfusions after instrumental vaginal delivery 0.40 3 1022 Beta (335, 83 578) The National Board of
Health and Welfare17
Blood transfusions after spontaneous vaginal delivery 0.13 3 1022 Beta (1415, 1 107 807) The National Board of
Health and Welfare17
Sepsis after caesarean section 0.15 3 1022 Beta (15, 9883) Kankuri et al.18
Sepsis after spontaneous and instrumental vaginal delivery 0.48 3 1023 Beta (16, 33 559) Kankuri et al.18
Metabolic acidosis after CTG 0.12 3 1021 Beta (49, 3967) Neilson5
RR metabolic acidosis after STanalysis 0.64 Gamma (7.92, 0.08) Neilson5
Caesarean section after CTG 0.86 3 1021 Dirichlet (378, 619, 3404) Neilson5
Instrumental vaginal delivery after CTG 0.14 Neilson5
Spontaneous vaginal delivery after CTG 0.77 Neilson5
RR caesarean section after STanalysis 0.97 Gamma (186.12, 0.01) Neilson5
RR instrumental delivery after STanalysis 0.87 Gamma (269.46, 0.003) Neilson5
Fetal blood sampling after CTG 0.11 Beta (490, 3911) Neilson5
RR fetal blood sampling after STanalysis 0.76 Gamma (141.02, 0.01) Neilson5
Base deﬁcit of .16 mmol/l in the metabolic acidosis group 0.28 Beta (24, 63) O ¨ stergo ¨tland County
Council19
Base deﬁcit of 8–12 mmol/l in the no metabolic acidosis group 0.76 3 1021 Dirichlet (371, 1418, 3063) O ¨ stergo ¨tland County
Council19
Base deﬁcit of 4–8 mmol/l in the no metabolic acidosis group 0.29 O ¨ stergo ¨tland County
Council19
Base deﬁcit of ,4 mmol/l in the no metabolic acidosis group 0.63 O ¨ stergo ¨tland County
Council19
No encephalopathy when base deﬁcit .16 mmol/l 0.39 Dirichlet (23, 12, 17, 7)* Low et al.12
Minor encephalopathy when base deﬁcit .16 mmol/l 0.20 Low et al.12
Moderate encephalopathy when base deﬁcit .16 mmol/l 0.29 Low et al.12
Severe encephalopathy when base deﬁcit .16 mmol/l 0.12 Low et al.12
No encephalopathy when base deﬁcit 12–16 mmol/l 0.72 Dirichlet (42, 11, 4, 1)* Low et al.12
Minor encephalopathy when base deﬁcit 12–16 mmol/l 0.19 Low et al.12
Moderate encephalopathy when base deﬁcit 12–16 mmol/l 0.68 3 1021 Low et al.12
Severe encephalopathy when base deﬁcit 12–6 mmol/l 0.17 3 1021 Low et al.12
No encephalopathy when base deﬁcit 8–12 mmol/l 0.83 Dirichlet (48, 10, 0, 0)* Low et al.12
Minor encephalopathy when base deﬁcit 8–12 mmol/l 0.17 Low et al.12
Moderate encephalopathy when base deﬁcit 8–12 mmol/l 0.16 3 1023 Low et al.12
Severe encephalopathy when base deﬁcit 8–12 mmol/l 0.22 3 1023 Low et al.12
No encephalopathy when base deﬁcit 4–8 mmol/l 0.95 Dirichlet (53, 1, 2, 0)* Low et al.12
(continued)
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cases cited;23 the other 2 cases, currently being investigated,
were in this study included in a sensitivity scenario.
In the Cochrane review used in the analysis, metabolic
acidosis was deﬁned as cord artery blood pH of less than
7.05 and a base deﬁcit of more than 12.0 mmol/l.5 To enable
the transition from metabolic acidosis to encephalopathy in
the model, we used estimates from a trial12 investigating the
level of base deﬁcit associated with encephalopathy. In this
trial, the distribution of different stages of encephalopathy
was presented in four different groups of children. The four
groups were differentiated by the base deﬁcit values detected
in the children’s cord artery blood: children with a base deﬁcit
of 4–8, 8–12, 12–16, and >16 mmol/l. Then, using the defi-
nition of metabolic acidosis as a base deficit of more than
12.0 mmol/l, we were able to create a connection between
metabolic acidosis and encephalopathy. To incorporate the
distribution of base deficit levels in children born in Sweden,
we used base excess data19 from Vrinnevi Hospital in Norr-
ko ¨ping (base excess levels for 4939 of 5984 children born in
2004–06). Children having a base deficit of less than 4 mmol/l
were not included in the study by Low et al.,12 this group did
in our model not include any cases of moderate or severe
encephalopathy. The probability of children being diagnosed
with cerebral palsy depends on the presence and severity of
newborn encephalopathy. The estimates we used for this
relationship were based on a trial by Badawi et al.13 The same
trial was used in determining the probability of the differ-
ent degrees of cerebral palsy. The probability of death after
encephalopathy, was retrieved from a meta-analysis20 of long-
term adverse outcomes for newborns. The meta-analysis in-
cluded studies following the children for a period of between
18 months and 3.5 years.
As previously mentioned, we have in our base-case analysis
modelled the relationship between surveillance method and
encephalopathy through metabolic acidosis. Due to the com-
plexity of this relationship, one would preferably have long-
term data investigating the direct effect of surveillance
method on encephalopathy. However, the only current trial
specifying the numbers of moderate and severe cases of
encephalopathy, thus providing the possibility of an extrap-
olation to cerebral palsy, is a study by Noren et al.24 The
number of participants in this study is in our opinion, how-
ever, too few to be considered to correctly represent the
distribution of an unlikely event, such as encephalopathy.
To eliminate some of the structural uncertainty related to
Table 1. (Continued)
Probabilities Mean value Distribution References
Minor encephalopathy when base deﬁcit 4–8 mmol/l 0.18 3 1021 Low et al.12
Moderate encephalopathy when base deﬁcit 4–8 mmol/l 0.36 3 1021 Low et al.12
Severe encephalopathy when base deﬁcit 4–8 mmol/l 0.15 3 1023 Low et al.12
Cerebral palsy after moderate encephalopathy 0.84 3 1021 Beta (15, 163) Badawi et al.13
Mortality the ﬁrst 2 years after moderate encephalopathy 0.62 3 1021 Beta (19, 287) van de Riet et al.20
Cerebral palsy after severe encephalopathy 0.23 Beta (17, 56) Badawi et al.13
Mortality the ﬁrst 2 years after severe encephalopathy 0.67 Beta (124, 60) van de Riet et al.20
Proportion of severe cerebral palsy in children diagnosed with
moderate or severe encephalopathy
0.46 Dirichlet (15, 6, 5, 6) Badawi et al.13
Proportion of moderate cerebral palsy in children diagnosed with
moderate or severe encephalopathy
0.19 Badawi et al.13
Proportion of mild cerebral palsy in children diagnosed with
moderate or severe encephalopathy
0.16 Badawi et al.13
Proportion of minimal cerebral palsy in children diagnosed with
moderate or severe encephalopathy
0.19 Badawi et al.13
Cerebral palsy in children with no or mild encephalopathy 0.12 3 1022 Beta (99, 82 620) Badawi et al.13
Proportion of severe cerebral palsy in children diagnosed with
no or mild encephalopathy
0.25 Dirichlet (25, 30, 32, 12) Badawi et al.13
Proportion of moderate cerebral palsy in children diagnosed with
no or mild encephalopathy
0.30 Badawi et al.13
Proportion of mild cerebral palsy in children diagnosed with no
or mild encephalopathy
0.32 Badawi et al.13
Proportion of minimal cerebral palsy in children diagnosed with
no or mild encephalopathy
0.12 Badawi et al.13
RR, relative risk.
*To adjust for the zero counts in some of the events in these distributions a non-informative prior of 0.01 was used in the probabilistic sensitivity
analysis.
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pathy, we have included a sensitivity scenario where the rate of
encephalopathy is based on the data from Noren et al.24
Costs
The cost parameters used in the model can be found in
Table 2. The costs of giving birth by caesarean section, instru-
mental vaginal delivery, and spontaneous vaginal delivery
include the costs of the mode of delivery plus the costs of
treating potential complications in the mother. To calculate
the cost per delivery of using either ST analysis or CTG, the
following formula was used:
Cdelivery =
ð
Cdevice · ndevices
A1;r Þ + Celectrodes
nbirths · phigh risk
;
where Cdevice represents the cost of purchasing either CTG
or ST analysis, Celectrode the annual cost of scalp electrodes,
ndevices the number of devices per obstetric unit, nbirths the
number of deliveries per year at the obstetric unit, phigh risk
the proportion of deliveries in which fetal surveillance with
a scalp electrode is estimated to be used, l the life span of the
equipment, r the discount factor, and Al,r the annuity factor.
The life span of the equipment was set to 7 years, and the
annuity factor was 6.23.
The number of devices per obstetric unit and the number
of deliveries per obstetric unit are based on data from Link-
o ¨ping University hospital (Table 2). To elucidate the general-
isability of our results to other settings, a two-way sensitivity
analysis was performed in which we simultaneously varied the
number of devices per obstetric unit and the proportion of
deliveries monitored with a scalp electrode. The analysis was
performed for the range of two to eight devices and a pro-
portion of monitored deliveries of 0.1–0.6.
Even though the ST analysis guidelines advocate consistent
training in ST interpretation, only the training costs that
Table 2. Cost parameters in the model
Cost estimates Cost References
Caesarean section (per delivery) e4170 O ¨ stergo ¨tland County Council25
Instrumental delivery (per delivery) e1990 O ¨ stergo ¨tland County Council25
Spontaneous vaginal delivery (per delivery) e1470 O ¨ stergo ¨tland County Council25
Use of STanalysis (per delivery) e53
Use of CTG (per delivery) e23
Cost of purchasing STanalysis (per device) e29,800 SBU1
Cost of purchasing CTG (per device) e14,900 SBU1
Number of devices per obstetric unit 4 Division of Obstetrics and Gynaecology, Linko ¨ping University Hospital
Personal communication
Number of deliveries per obstetric unit 2500 Personal communication
Proportion of deliveries monitored with a scalp electrode 20% SBU1 and personal communication
Scalp electrode for STanalysis e4.15 Neoventa Medical AB26
Scalp electrode for CTG e3.94 Medexa Diagnostisk Service AB27
Training in STanalysis interpretation e32,400 O ¨ stergo ¨tland County Council25 and personal communication
Cost per hour of a midwife e35 O ¨ stergo ¨tland County Council25
Cost per hour of a physician e71 O ¨ stergo ¨tland County Council25
Cost per hour of an assistant nurse e25 O ¨ stergo ¨tland County Council25
Fetal scalp blood sampling (per sample) e28 Personal communication and Triolab AB28
Care at SCBU metabolic acidosis e750 County Councils of O ¨ stergo ¨tland Kalmar and Jo ¨nko ¨ping30
Care at SCBU mild encephalopathy e750 County Councils of O ¨ stergo ¨tland Kalmar and Jo ¨nko ¨ping30
Care at SCBU moderate encephalopathy e2110 County Councils of O ¨ stergo ¨tland Kalmar and Jo ¨nko ¨ping30
Care at SCBU severe encephalopathy e2490 County Councils of O ¨ stergo ¨tland Kalmar and Jo ¨nko ¨ping30
Pulmonary embolism (per woman) e3200 County Councils of O ¨ stergo ¨tland Kalmar and Jo ¨nko ¨ping29
Deep vein thrombosis (per woman) e2720 Levin and Bergqvist31
Cerebral thrombosis (per woman) e4040 Ghatnekar et al.32
Blood transfusion (units per woman) e230 County Councils of O ¨ stergo ¨tland Kalmar and Jo ¨nko ¨ping29
Sepsis (per woman) e4370 County Councils of O ¨ stergo ¨tland Kalmar and Jo ¨nko ¨ping29
Cerebral palsy 0–1 years (per year) e58,820 Svensson et al.33 and Bouwes34
Cerebral palsy 2–4 years (per year) e35,680 Svensson et al.33 and Bouwes34
Cerebral palsy 5–17 years (per year) e41,480 Svensson et al.33 and Bouwes34
Cerebral palsy 181 years (per year) e70,100 Svensson et al.33 and Bouwes34
Production losses for individuals with severe cerebral palsy,
after 20 years of age (per year)
e35,790 Statistics Sweden35
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analysis. This is due to the fact that CTG also requires con-
tinuous training and that training in ST analysis interpreta-
tion is thought to affect the interpretations of CTG in
a positive way.36 The ST analysis introduction cost was
included in the cost per delivery for the ST analysis strategy
and was calculated for 6 hours of training for 18 physicians
and 45 midwives plus 136 physician hours and 160 midwife
hours of teaching (personal communication). Included in the
cost of taking a scalp blood sample were the costs of using
the ABL-5 blood-gas analyser (Radiometer, Copenhagen,
Denmark), the time of a doctor, a midwife, and an assistant
nurse, two clinitubes, and a blood-gas syringe.28 Costs for care
at Special Care Baby Unit (SCBU) were included for children
with metabolic acidosis and different levels of encephalopa-
thy. The average length of admission to SCBU for children
with metabolic acidosis was 2.54 days (SE 0.69). The corre-
sponding length of stay at SCBU for mild, moderate, and
severe encephalopathy was 7.75 (SE 1.70), 10.75 (SE 2.32),
and 12.20 (SE 4.60) days, respectively.24
The costs associated with the ﬁrst 8 years of life for children
with severe cerebral palsy were drawn from a study of the costs
of the erroneous management of delivery.33 In this particular
study, ﬁve of nine children had some degree of invalidity;
one to a degree of 50–70% and four to a degree of 71–
100%. Asthe primary diagnosis associated withsevereinjuries
due to erroneous management during labour has been dem-
onstrated elsewhere to be cerebral palsy,37 these costs are
employed in our model for children with severe cerebral
palsy. To determine the costs of cerebral palsy in individuals
older than 8 years, ﬁgures from an American cost-of-illness
study34 were used as weights to extrapolate the costs over
a lifetime horizon. To visualise the impact of this parameter
on the result, we have in addition to the probabilistic sensi-
tivity analysis included two sensitivity scenarios in which we
have augmented and decreased the costs by 50%. Individuals
with severe cerebral palsy were assumed to be unable to work.
The annual costs of productivity losses were drawn from ofﬁ-
cial data collected by Statistics Sweden.35 In the model, the
average age of beginning a ﬁrst job was set to 20 years and
productivity losses were calculated for ages 20–64 years. The
effect of including these productivity losses in our analysis
was tested in a sensitivity analysis.
Life expectancy and QALYs
To the best of the authors’ knowledge, no complete age-speciﬁc
standard mortality statistics are available for the deﬁnitions
of cerebral palsy used in the model. However, evidence of
survival time for the deﬁnitions used in the model does exist
for the time interval of 25–40 years of age, dependent on the
degree of cerebral palsy.14 The ﬁndings of this study were
incorporated into our model by employing a parametric
time-to-event survival model with a Weibull distribution.38
The results of the Weibull regression indicated a decreasing
hazard of death with respect to age as the ancillary gamma
parameter declined below 1 (i.e. –0.2, SE 0.08); the constant
in the regression was –3.51 (SE 0.21). Using appropriate for-
mulas, the ﬁtted hazard function was transformed to yearly
probabilities of death. The nature of the Weibull regression
will lead to a continuing decrease in the probability of death,
not accounting for the natural increase late in life. The prob-
ability of death was therefore only based on the regression as
long as it remained above the standard mortality.39 As the
probability of death for the children with encephalopathy
already is included in the model, the ﬁrst 2 years of the curves
were excluded for these children to avoid double counting of
the death risk. Due to the uncertainty in this extrapolation of
death risk, a sensitivity scenario was analysed based on a time
horizon of only 25 years.
Health outcomes in the analysis were expressed as QALYs.
The QALY weights used in the model are shown in Table 3.
How these are used in the calculation of QALYs is illustrated
by an example of a QALY for a 40-year-old individual with
moderate cerebral palsy:
QALYmodCP =
UmodCP
UGeneral <30
· UGeneral40 · 1 year:
As QALY weights for individuals diagnosed with mild,
moderate, and severe cerebral palsy are only available for
adolescents,40 the UmodCP, representing the QALY weight
for children with moderate cerebral palsy, was divided by
UGeneral <30, representing the QALY weight for the corre-
sponding age group in the general population. This generated
an age- and severity-adjusted QALY factor that could be
Table 3. QALY weights
QALY weights References
Severe cerebral palsy 0.04 Rosenbaum et al.40
and Bax et al.41
Moderate cerebral palsy 0.45 Rosenbaum et al.40
and Bax et al.41
Mild cerebral palsy 0.84 Rosenbaum et al.40
and Bax et al.41
General population ,30 0.90 Burstrom et al.42
General population 30 0.88 Burstrom et al.42
General population 40 0.87 Burstrom et al.42
General population 50 0.85 Burstrom et al.42
General population 60 0.82 Burstrom et al.42
General population 70 0.78 Burstrom et al.42
General population 801 0.69 Burstrom et al.42
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1682 ª 2008 The Authors Journal compilation ª RCOG 2008 BJOG An International Journal of Obstetrics and Gynaecologymultiplied by the utility of the general population with the
corresponding age, UGeneral40. In this way, we incorporated
a decrease in QALY weights with respect to increasing age
equal to that of the general population.42 As cerebral palsy
has been internationally deﬁned as a nonprogressive impair-
ment,43 we incorporated no additional decrease in the QALY
weights with respect to age for individuals with cerebral palsy
compared with the general population.
The QALY weights used in our analysis were classiﬁed
according to the Gross Motor Function Classiﬁcation System
(GMFCS). As the degrees of cerebral palsy used in our model
were not based on the GMFCS levels, we assumed that the
values for level I, levels II and III, and levels IV and V corre-
spond to how Blair et al.14 deﬁned mild, moderate, and severe
cerebral palsy, respectively.41
Analysis
According to recent guidelines, the model was analysed using
second-order Monte-Carlo simulation to reﬂect uncertainty
in the model inputs.44 In this approach, values are drawn
randomly from deﬁned probability distributions in the
model, and costs and QALYs are established for both strate-
gies. This process is repeated 5000 times to provide 5000
estimates of the ICER, reﬂecting the uncertainty in the out-
come. The uncertainty surrounding the estimated ICER also
reﬂects the uncertainty surrounding the decision to employ
a ST analysis strategy rather than a CTG strategy. The pro-
portion of the 5000 simulations resulting in an ICER below
the threshold value at which decision makers are willing to
pay for a QALY represents the probability of ST analysis being
cost-effective.45 As there is no single established true willing-
ness-to-pay for a QALY, this probability can be presented for
a range of willingness-to-pay values in so-called cost-effec-
tiveness acceptability curves (CEACs), allowing the decision
maker to select the willingness-to-pay for a speciﬁc treatment
strategy and then assess the probability that the strategy is
cost-effective. Costs and QALYs were discounted by 3% per
annum, in line with recent guidelines.46
Results
The results of the base-case analysis (Table 4) showed that the
use of ST analysis results in a gain in QALYs at a lower cost
and therefore dominates CTG. The lower overall cost of using
the ST analysis strategy, despite the higher initial costs of ST
analysis, is partly due to the avoidance of costs related to
cerebral palsy. However, even in the time period until just
after delivery, ST analysis is cost saving in comparison with
CTG alone (Table 5). This is explained by the lower rate of
complicated deliveries, cases of metabolic acidosis, and cases
of encephalopathy in the ST analysis arm.
The probabilistic sensitivity analysis demonstrated that the
probability of ST analysis being cost-effective was more than
0.9 for all willingness-to-pay values over e9000, as shown in
the CEAC presented in Figure 2.
Sensitivity analysis
None of the results from the sensitivity scenarios led to a dif-
ferent conclusion concerning the cost-effectiveness of ST
analysis (Table 6).
Except for the scenario with eight devices and a proportion
of 0.1 deliveries monitored with a scalp electrode (31.25 deliv-
eries per equipment and year), all other scenarios varying the
number of devices and proportionof deliveries monitored with
either CTG or ST analysis, resulted in ST analysis still domi-
natingtheCTGstrategy.Forthescenariowitheightdevicesand
0.1 deliveries monitored with a scalp electrode, the costs were,
however, so low that ST analysis would still be considered cost-
effective, yielding a incremental cost of e11 and an incremental
effect of 0.0054 QALYs, that is an ICER of e2105 per QALY.
Discussion
The purpose of this study was to evaluate the cost-effective-
ness of ST analysis compared with that of CTG alone. Our
Table 4. Comparison of costs and effects
Method Costs Incremental costs Effectiveness (QALYs) Incremental effectiveness ICER
STanalysis e3349 256 27.1636 0.0054 Dominating
CTG e3405 27.1582
Table 5. Contribution to total costs (calculated for one delivery)
Costs per delivery CTG STanalysis Incremental cost
Equipment cost e23 e53* e30
Delivery method 1 care
at SCBU
e2163 e2118 2e45
Severe cerebral palsy e983 e949 2e34
Production losses e236 e229 2e7
Total cost e3405 e3349 2e56
*Introductional training in STanalysis interpretation is included
in the equipment cost.
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analysis strategy is the cost-effective alternative. When includ-
ing both the immediate direct treatment costs at the hospital
and the lifetime costs for individuals with severe cerebral
palsy, the results indicate that ST analysis is a cost-saving
method compared with CTG. However, also when consider-
ing only the treatment costs associated with the immediate
care at the hospital, our study shows that ST analysis is cost
saving, which means that the additional cost of using the ST
analysis device instead of CTG is more than outweighed by
the costs saved by avoiding caesarean sections, instrumental
vaginal deliveries, cases of metabolic acidosis, and cases of
encephalopathy. This result is in contradiction to previous
results in the cost-analysis performed by NICE,7 which indi-
cates that the cost of purchasing the ST analysis equipment is
higher than the potential cost savings from reduced operative
deliveries. Their analysis did, however, not include costs for
care of children with metabolic acidosis and neonatal
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Figure 2. The cost-effectiveness acceptability curve.
Table 6. Results of the sensitivity scenarios
Method Costs Incremental
costs
Effectiveness
(QALYs)
Incremental
Effectiveness
ICER
Excluding data for metabolic acidosis
in the trial by Ojala et al.4
STanalysis e3308 2e115 27.1660 0.0092 Dominating
CTG e3423 27.1568
25-year time horizon STanalysis e2800 2e37 16.4671 0.0033 Dominating
CTG e2837 16.4638
Including two extra cases of metabolic acidosis
in the STanalysis arm
STanalysis e3357 2e49 27.1630 0.0048 Dominating
CTG e3405 27.1582
Excluding production losses for individuals
with severe cerebral palsy
STanalysis e3120 2e48 27.1636 0.0054 Dominating
CTG e3168 27.1582
Using data on encephalopathy from the
Swedish RCT24
STanalysis e2363 2e228 27.1682 0.0291 Dominating
CTG e2592 27.1973
Augmenting the costs of severe cerebral
palsy with 50%
STanalysis e3823 2e73 27.1636 0.0054 Dominating
CTG e3896 27.1582
Decreasing the costs of severe cerebral
palsy with 50%
STanalysis e2874 2e40 27.1636 0.0054 Dominating
CTG e2914 27.1582
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the CTG alone strategy. The ST analysis equipment consists of
both the CTG and the additional ST analysis and is, when
implemented, thought to replace the alternative of CTG
alone. We therefore argue that the equipment cost of ST
analysis must be compared with that of CTG alone. The costs
of introductory training was in our analysis, however, only
included for the ST analysis strategy and have been calculated
for the circumstances at Linko ¨ping University Hospital. So
has the equipment number per obstetric unit and the number
of deliveries per obstetric unit, both used in the calculations of
the costs of equipment per delivery. Using these data in the
calculations of the equipment, cost per delivery corresponds
to using a number of approximately 125 deliveries per device
and year. The conclusion regarding the cost-effectiveness of
ST analysis did, however, not change when in a scenario anal-
ysis varying the number of devices per obstetric unit and the
proportion of deliveries monitored with a scalp electrode.
This therefore warrants a generalisability of our results to
other settings.
That ST analysis, compared with CTG alone, helped reduce
the number of cases of metabolic acidosis was previously
demonstrated in a Cochrane review.5 Our analysis demon-
strates that the use of ST analysis also results in a gain in
QALYs, when taking into account the effects of cerebral palsy
and death. As cerebral palsy in our model was deﬁned as
a nonprogressive impairment (i.e. the physical state was
assumed not to change with age only because of the disease),
the QALY weights we used in our analysis decrease with age
based on the changes of quality-of-life data in the general
population. We do not know how an individual with cerebral
palsy perceives that the quality of life changes as he or she
grows older. The difference in mobility between people with
and without cerebral palsy is, for example, believed to increase
with age during childhood and adolescence, but an individual
with cerebral palsy may, however, also cope with the disease
with time. Concerning the lifetime costs of cerebral palsy, no
cost data were available for the costs of care for individuals
with mild and moderate cerebral palsy. Including such costs
would have strengthened the cost-effectiveness of ST analysis
further, as according to our model, there are fewer cases of
cerebral palsy after using ST analysis than after using CTG
alone. Production losses were included for both the relatives
of children with severe cerebral palsy and the children them-
selves as adults.33,35 The sensitivity scenario excluding the
costs of production losses for the children with cerebral palsy
did not yield results changing the conclusion that ST analysis
should be considered cost-effective.
The link between metabolic acidosis and cerebral palsy in
our model was established using previous research into this
relationship. This was carried out to model the path fol-
lowed by a child affected by oxygen deﬁciency severe enough
to cause cerebral palsy. The concept of extrapolating costs
and outcomes by modelling a longer time period than that
for which available trial data exist might seem clinically
doubtful. When evaluating cost-effectiveness, however, the
appropriate time horizon should be the time over which the
costs and effects of the alternatives might differ.8 The time
the children remain alive is often the only relevant time
horizon, even if the children are never followed for that
period in trials. In this study, evaluating different methods
of fetal monitoring, the information gap between what has
been observed in clinical trials and the expected future
effects on health and costs literally includes a whole lifetime.
The extrapolation to cerebral palsy and death was in our
model performed in two steps involving various data sour-
ces. To validate the model, one could compare the proba-
bility of developing cerebral palsy according to this model
with outcomes in clinical studies of the subject. Himmel-
mann et al.47 concluded that the mean prevalence of term
cerebral palsy in Sweden was 11.1 per 10 000 live births. The
prevalence of cerebral palsy in our model was higher, 21.30
and 21.83 of 10 000 in the ST analysis and CTG arms,
respectively, a difference thatc o u l dp e r h a p sb ee x p l a i n e d
by the use of Australian and Canadian studies when deter-
mining the probabilities of encephalopathy and cerebral
palsy (the overall rate of term cerebral palsy in the Australian
study was 15.8 per 10 000).13 We also compared the preva-
lence of encephalopathy in the model with those established
in the literature. Badawi et al.48 have estimated the general
b i r t hp r e v a l e n c eo fm o d e r a t eo rs e v e r ee n c e p h a l o p a t h yt ob e
3.8 per 1000 term live births. In comparison with this num-
ber, the rates of encephalopathy in our model are high (12.1
and 12.8 per 1000 in the CTG and ST analysis arms, respec-
tively). However, the difference seems to be mainly due to an
augmented number of encephalopathy due to causes other
than metabolic acidosis, and this affects the cost-effective-
ness of ST analysis negatively. According to Low et al.,12 the
prevalence of metabolic acidosis plus moderate or severe
encephalopathy is approximately 3 per 1000. In our model,
the same number is 2.1 and 1.4 per 1000 births in the CTG
arm and ST analysis arm, respectively, which is reasonable as
we have lower rates of metabolic acidosis. The sensitivity
scenario investigating the use of the data on encephalopathy
from Noren et al.24 showed that ST analysis was even more
cost-effective when basing our model on these direct
observations.
The validity of our results is of course dependent on the
validity of the studies upon which it has been based. We
therefore ﬁnd it important to mention that the results of
two of the included RCTs have been questioned.21,22 The
criticism of Ojala et al.4 concerned the method used to mea-
sure metabolic acidosis. The inclusion of this trial in the base-
case analysis reduced the difference between the two strategies
incasesofmetabolicacidosisandoperativedeliveries.However,
ST analysis was still the dominant intervention, and excluding
The cost-effectiveness of fetal monitoring with ST analysis
ª 2008 The Authors Journal compilation ª RCOG 2008 BJOG An International Journal of Obstetrics and Gynaecology 1685the results of this trial from the sensitivity analysis meant that
using ST analysis resulted in even higher gains of QALY at
lower costs. Amer-Wa ˚hlin et al.2 has on the other hand been
criticised for excluding cases of metabolic acidosis from the
ST analysis arm. When in a sensitivity scenario including two
additional cases of metabolic acidosis in the ST analysis arm
the differences in QALYs and costs between the two strategies
were slightly reduced, but the ST analysis strategy was still
dominating the CTG strategy.
As pointed out earlier in the discussion, our analysis is not
without limitations. With regard to the decision on whether
ST analysis should be implemented, results from along-term
trial would of course be desirable. However, despite lack of
such evidence, decisions concerning the method of fetal sur-
veillance will still have to be made. It is important to remem-
ber that the alternative to using the current approach of
synthesising current best available evidence is implicit
decision-making with little or no information about the
rationale for decisions. By employing a probabilistic deci-
sion-analytic model, we have been able to calculate the cost-
effectiveness of ST analysis and take the uncertainty of
the current evidence into account. Although some of the
assumptions made in the analysis may seem dubious to
the reader, all sensitivity scenarios have shown that the
results are robust with regard to these assumptions. Based
on our results, a decision maker may make an informed
decision while waiting for the results from a long-term trail.
As the ﬁrst study fully assessing the cost-effectiveness of ST
analysis, it contributes valuable information, both concern-
ing the cost-effectiveness ratio and the uncertainty concern-
ing the decision.
Conclusions
According to the results of our evaluation, the use of ST
analysis results both in a gain in QALYs and in lower costs
when compared with CTG alone. Thus, ST analysis is the
cost-effective alternative when used in complicated term
deliveries in which a decision has been made to monitor the
fetus with a scalp electrode.
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